This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G11.4 | Special Copayment Reduction: V123 |
| B. Synonyms | Hereditary spastic paraplegia, Strümpell-Lorrain syndrome |
| C. Adult onset | Moderate likelihood of first onset in adulthood — the SPG4/SPAST type has a wide age of onset (childhood to old age), on average in the 30s~40s, with some cases of childhood onset |
| 1. History | First described by Strümpell in 1880, jointly described with Lorrain in 1900, SPG gene classification system established |
| 2. Causes | More than 80 SPG genes; SPG4 (SPAST mutations) most common (40% of the AD form); genes related to axonal transport and mitochondrial function |
| 3. Genetics | Various inheritance patterns: autosomal dominant (AD, most common), autosomal recessive (AR), X-linked recessive |
| 4. General epidemiology | Prevalence about 2~10/100,000; the most common group of causes of hereditary progressive lower limb spasticity |
| 5. Pathophysiology | Selective degeneration of the distal ends of corticospinal tract axons (at the lumbosacral level); dysfunction of microtubule severing, axonal transport, and mitochondria |
| 6. Symptoms | Spastic gait disturbance of the lower limbs (pure form); in the complex form, additional neurological, ophthalmic, cognitive, and skin symptoms |
| 7. Signs | Lower limb spasticity, hyperactive deep tendon reflexes, positive Babinski sign, spastic gait of the lower limbs, bladder dysfunction |
| 8. Screening | SPG gene panel and brain/spinal cord MRI when there is a family history + spastic gait of the lower limbs |
| 9. Diagnosis | SPG4 (SPAST) gene tested first; comprehensive gene panel if negative; spinal cord MRI to confirm atrophy |
| 10. Treatment | Antispasticity agents (baclofen, tizanidine), Botox, physical therapy, bladder treatment, orthoses; disease-modifying treatment under study |
| 11. Prognosis | Mostly slowly progressive; survival generally normal; loss of ambulation only in some; reduced quality of life |
| 12. Prevention | Genetic counseling, family testing and prenatal diagnosis according to inheritance pattern |
| 13. References | Harding AE Brain 1983 and 9 other papers |
Hereditary spastic paraplegia (HSP) dates back to 1880, when the German neurologist Adolf Strümpell first described a familial disorder in which two brothers showed progressive lower limb spasticity and gait disturbance. Later, in 1888, he reported further family cases and named it "familial spastic paralysis." In 1888, the French neurologist Lorrain also independently reported similar cases, and the disease subsequently also came to be called 'Strümpell-Lorrain syndrome.'
In the early 20th century, neuropathological studies established that selective degeneration occurs at the distal ends of axons in the corticospinal tracts and the dorsal columns of the spinal cord. In 1993, Anne-Marie Harding proposed clinical criteria classifying HSP into pure and complex forms, laying the foundation for the classification still used today. After the first HSP gene locus (SPG1, X-linked) was identified in 1994, the SPG gene numbering system was introduced.
The biggest turning point was the identification of the SPG4 (SPAST) gene in 1999, which established SPG4 as the most common cause among all HSP patients. Subsequently, dozens of genes, including SPG3, SPG5, SPG7, SPG11, and SPG15, were discovered, and currently more than about 80 HSP genotypes (SPG numbering system) are registered. With advances in next-generation sequencing technology, new genes continue to be discovered.
HSP is caused by mutations in more than about 80 SPG (spastic paraplegia gene) genes, which are classified by function into several major pathogenic categories. Microtubule function and axonal transport: SPG4 (SPAST, spastin) is the most common, accounting for about 40% of autosomal dominant HSP. Spastin is a microtubule-severing enzyme belonging to the AAA ATPase family. Loss of spastin function impairs microtubule assembly and remodeling within corticospinal tract axons, resulting in impaired axonal transport.
Regulation of endoplasmic reticulum (ER) morphology: SPG3A (ATL1, atlastin-1), SPG12 (RTN2), SPG31 (REEP1), and others are involved in maintaining tubular ER morphology. Lipid metabolism: SPG5 (CYP7B1, oxysterol metabolism), SPG28 (DDHD1), and others. Mitochondrial function: SPG7 (paraplegin, a mitochondrial protease), SPG31 (REEP1), SPG13 (HSP60), and others are involved in mitochondrial function. Lysosomal and autophagy pathways: causative genes of complex HSP such as SPG11 (spatacsin) and SPG15 (ZFYVE26) belong to this category.
What they have in common is that all of these genes make selectively vulnerable the distal ends of the axons of upper motor neurons of the corticospinal tract, the longest nerve fibers—the neurons serving the lower limbs at the lumbosacral level. This explains the typical lower limb spasticity pattern of pure HSP.
HSP includes three inheritance patterns: autosomal dominant (AD), autosomal recessive (AR), and X-linked recessive. Adult onset, a positive family history, and pure HSP are mostly autosomal dominant, while childhood onset, consanguineous parents, and complex HSP suggest autosomal recessive inheritance.
In autosomal dominant HSP, SPG4 (SPAST), SPG3A (ATL1), and SPG31 (REEP1) are the main genes, with SPG4 the most common. SPG4 has variable penetrance, so clinical expression within a family can differ greatly even with the same mutation. In autosomal recessive HSP, SPG11, SPG15, SPG7, SPG5, and others are relatively common, and a complex phenotype is often seen. X-linked forms include SPG1 (L1CAM), SPG2 (PLP1), and others, and typically affect only males.
De novo mutations also occur not uncommonly in SPG4 and other forms; in such cases there is no family history and the case may appear sporadic. Genotype-phenotype correlations are complex, and both pure and complex forms can occur with different mutations in the same gene. A clinical diagnosis is possible even when genetic testing is negative, and in such cases retesting is considered when new genes are discovered.
The prevalence of HSP is estimated at about 2~10/100,000 people, varying with study method and region. It belongs to the most common group among diseases causing hereditary progressive lower limb spasticity. The autosomal dominant form is the most common, and prevalence differs by population. Patients with SPG4 and other mutations have also been reported in Korea, but accurate national prevalence statistics are lacking.
Age of onset is highly variable. SPG4 has a wide range of onset from childhood to old age, with a median usually in the 30s~40s. SPG3A often begins in childhood, and SPG11 commonly begins in adolescence or early adulthood. The male-to-female ratio depends on the inheritance pattern and is generally equal except in X-linked forms. As the diagnostic rate improves with the discovery of new genes and wider availability of genetic testing, the actual number of prevalent patients is trending upward.
The core pathophysiology of HSP is selective distal degeneration of the corticospinal tract axons of upper motor neurons, particularly the longest fibers—the neurons serving the lower limbs at the lumbosacral level. This is a length-dependent degeneration pattern: because lower limb neurons are much longer than those of the upper limbs, they are more vulnerable to impaired axonal transport. When anterograde axonal transport, which supplies mitochondria, organelles, and neurotransmitters to the distal ends of axons, is impaired, it becomes difficult to maintain axonal energy supply and structure.
In SPG4 (spastin), loss of the microtubule-severing enzyme function makes the microtubule network within corticospinal tract axons abnormally dense and makes branching and network remodeling difficult. Microtubule abnormalities directly impair kinesin- and dynein-based cargo transport, leading to oxidative damage, mitochondrial dysfunction, and deficiency of synaptic materials at the distal ends of axons. In mutations of ER morphology-regulating genes (ATL1, REEP1), abnormal ER distribution arises in corticospinal tract axons, causing problems in the regulation of calcium homeostasis within axons.
In complex HSP (SPG11, SPG15, etc.), impairment of the lysosomal and autophagy pathways causes accumulation of protein aggregates and neuronal toxicity, and multiple neural structures, such as the corpus callosum, cerebellum, and peripheral nerves, are damaged as well. This is why complex HSP is accompanied by cognitive decline, cerebellar signs, and peripheral neuropathy.
HSP is clinically classified into pure HSP and complex HSP. In the pure form, the main symptoms are progressive lower limb spasticity and weakness and bladder dysfunction. It usually begins gradually and progresses over decades, and walking difficulty is the main functional impairment. The first symptoms are the feet dragging on the ground or a feeling of stiffness when walking, and frequent tripping and falling. Over time, climbing stairs, walking fast, and walking long distances become increasingly difficult.
Bladder dysfunction (urge incontinence, urinary frequency, urinary hesitancy) occurs in about 50~70% and, in severe cases, greatly interferes with daily life. Foot deformities (pes cavus, spastic hallux valgus) are common and result from spastic muscle imbalance. Reduced vibration sense in the legs occurs in some. The upper limbs are generally spared, and upper limb symptoms appear in the complex form or, rarely, in severe pure forms.
In complex HSP, various additional signs are present, such as cognitive impairment and dementia, cerebellar ataxia, visual impairment (optic atrophy, macular degeneration), hearing impairment, peripheral neuropathy, skin abnormalities, and skeletal abnormalities. In particular, in complex HSP with a thin corpus callosum (TCC) (SPG11, SPG15, etc.), corpus callosum atrophy is seen on MRI along with cognitive decline.
On neurological examination, spasticity of the lower limbs is most prominent. Resistance increases in both flexion and extension during passive joint movement, and velocity-dependent increase in muscle tone is characteristic. Hyperactive deep tendon reflexes of the lower limbs (knee and ankle reflexes) and ankle clonus are observed. A positive Hoffmann sign and plantar reflex (Babinski sign) confirm upper motor neuron signs.
On gait examination, stiff-legged gait, scissors gait, foot drop, and toe scuffing are observed. Foot deformities (pes cavus, spastic foot) may be seen, and findings of musculotendinous shortening (contracture) near the ankle and knee joints may also be present. On lower limb strength testing, weakness of the hip flexors and ankle dorsiflexors is common. The upper limbs are mostly spared. Evaluation of bladder function and measurement of post-void residual volume are needed.
Reduced vibration sense is found in some, which suggests involvement of the dorsal columns of the spinal cord. In the complex form, cerebellar signs, cognitive abnormalities, abnormal fundus examination, and signs of peripheral neuropathy additionally appear. Spine and chest X-rays check for associated spinal deformities, and bladder ultrasound and urodynamic studies help evaluate bladder dysfunction.
It is important to suspect HSP early in patients with spastic gait of the lower limbs and a family history. Particularly in autosomal dominant HSP, if a parent or child has a spastic gait, genetic testing should be actively performed. Even in sporadic cases without a family history, HSP should be included in the differential diagnosis of slowly progressive lower limb spasticity.
Genetic testing begins with SPG4 (SPAST) testing; if negative, testing of genes for common dominant forms, such as SPG3A and SPG31 (REEP1), is added. In childhood onset or complex phenotypes, a comprehensive gene panel that includes recessive forms (SPG11, SPG15, etc.) is needed. Clinical exome sequencing is useful for additional diagnosis in panel-negative patients.
Brain and spinal cord MRI is essential for excluding secondary causes (tumor, multiple sclerosis, cerebral infarction, cervical spondylosis, etc.) and for identifying characteristic findings of HSP (spinal cord atrophy, thin corpus callosum). Serum tests exclude treatable secondary causes of spasticity, such as vitamin B12 and E deficiency, thyroid function, and syphilis serology.
The clinical diagnosis of HSP is based on slowly progressive lower limb spasticity + gait disturbance + family history (or a positive genetic result). Excluding other causes is important. Confirmation is by genetic testing, including SPG4 (SPAST) gene sequencing and MLPA (copy number variant analysis). Because about 20% of SPAST mutations are large deletions or duplications, MLPA is essential.
Brain and spinal cord MRI identifies spinal cord atrophy (thoracic and cervical cord), thin corpus callosum (complex form), cerebellar atrophy (complex form), and so on. In complex HSP (SPG11, SPG15), corpus callosum atrophy and white matter signal abnormalities on T2-weighted images are characteristic. In pure SPG4, MRI may be normal or show only mild spinal cord atrophy. Nerve conduction studies assess the presence of peripheral neuropathy and motor nerve conduction velocity. Somatosensory evoked potential (SEP) testing may show delayed or absent lower limb somatosensory conduction.
The differential diagnosis includes multiple sclerosis, vitamin B12 or copper deficiency myelopathy, structural spinal cord compression (cervical spondylotic myelopathy), primary lateral sclerosis (PLS), spastic cerebral palsy, amyloid angiopathy, and others. Even when genetic testing is negative, if the clinical picture is consistent, the patient is managed with a clinical diagnosis of HSP, and next-generation gene panels or genome sequencing are reviewed again later.
There is currently no disease-modifying treatment for HSP, and the goals of treatment are symptom control and maintenance of function. Treatment of lower limb spasticity is central. Oral antispasticity agents include baclofen (first choice), tizanidine, and dantrolene. When control with oral drugs is insufficient and spasticity is severe, an intrathecal baclofen pump is an effective option. Botox (botulinum toxin) injections can be applied selectively to focal muscle spasticity to effectively reduce spasticity in specific muscle groups.
Physical therapy, including stretching, strengthening, balance training, and gait training, is essential for maintaining function and preventing contractures. An ankle-foot orthosis (AFO) compensates for foot drop and improves gait safety. Walking aids (rollator, cane) also help maintain mobility. For bladder dysfunction, anticholinergics (oxybutynin, solifenacin, etc.) are used for urgency and overactive bladder, and clean intermittent catheterization may be needed for urinary hesitancy.
Treatments under investigation include microtubule stabilizers targeting SPG4, support of spastin protein function, and drug repurposing studies. There are also preclinical studies of stem cell transplantation and gene therapy. Surgical correction (correction of foot deformities, tendon lengthening) may help improve function in patients who have developed contractures.
Pure HSP (including SPG4) is mostly a very slowly progressive disease, and survival does not differ greatly from that of the general population. Many patients retain some walking ability even decades after symptom onset, and functional independence can be maintained longer with orthoses and walking aids. Some patients, particularly those with early onset or severe lower limb spasticity, may lose the ability to walk (wheelchair dependence).
Complex HSP has a poorer prognosis. In SPG11 and other forms accompanied by cognitive decline, severe disability develops in the 20s~40s with rapid progression. When accompanied by optic atrophy or retinal degeneration, vision loss causes additional disability. In forms with peripheral neuropathy, walking difficulty is more complex.
Active rehabilitation, spasticity management, and bladder treatment contribute significantly to maintaining function and improving quality of life. Regular multidisciplinary follow-up (neurology, rehabilitation medicine, urology, orthopedics) is needed. Genetic counseling provides risk assessment and psychosocial support for family members.
Prevention approaches are based on the inheritance pattern of HSP. In autosomal dominant forms (SPG4, etc.), 50% of a patient's children inherit the pathogenic allele. Genetic counseling should convey this risk clearly, and transmission of the pathogenic gene can be prevented through preimplantation genetic testing (PGT-M) or prenatal diagnosis. Predictive genetic testing is offered on the premise of an autonomous adult decision, together with sufficient genetic counseling.
In autosomal recessive forms (SPG11, etc.), when both parents are carriers, 25% of their children are affected. Carrier testing is used to inform family planning decisions. In X-linked forms, 50% of the sons of a carrier woman are affected, so the approach is through prenatal sex determination and genetic testing. In all forms, genetic counseling and psychosocial support should be provided.
For secondary prevention, regular stretching and physical therapy to prevent contractures, environmental modification to prevent falls, and regular urologic follow-up to prevent bladder complications are important. Regular obstetric care during pregnancy is needed to differentiate spasticity caused by perinatal injury, and the mode of delivery is decided as needed.